Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) of 1 of the following subtypes:~  * Squamous cell carcinoma~ * Adenocarcinoma (including bronchoalveolar cell)~ * Large cell anaplastic carcinoma (including giant and clear cell carcinomas)~ * Poorly differentiated/not otherwise specified NSCLC~* Stage IIIA (T1-2, N2, M0 or T3, N1-2, M0) or IIIB (T4, any N, M0 or any T, N2-3, M0)~  * If the largest mediastinal node is \< 2.0 cm in diameter and this is the basis for stage III disease, then at least 1 of the nodes must be cytologically or histologically positive~* Unresectable disease~  * No totally resected tumors~* Tumors adjacent to a vertebral body allowed provided all gross disease can be encompassed in the radiation boost field and the boost volume is limited to \< 50% of the ipsilateral lung volume~* Measurable disease~* Transudate, cytologically negative, non-bloody pleural effusions allowed provided the tumor can be encompassed within a reasonable field of radiotherapy~  * Pleural effusions seen on a chest CT scan are allowed provided they are not visible on a chest x-ray and are too small to tap~* No asymptomatic or symptomatic brain metastases~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL (transfusion independent)~Hepatic~* Bilirubin ≤ 1.5 mg/dL~* SGOT (serum glutamic oxaloacetic transaminase) or SGPT (serum glutamate pyruvate transaminase) ≤ 3 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN~Renal~* Creatinine ≤ 2.0 mg/dL~Cardiovascular~* No significant history of cardiac disease~* No uncontrolled hypertension~* No unstable angina~* No uncompensated congestive heart failure~* No myocardial infarction within the past year~* No cardiac ventricular arrhythmias requiring medication~* LVEF (left ventricular ejection fraction) normal by MUGA (multi-gated acquisition) scan or echocardiogram~Pulmonary~* No history of interstitial pneumonitis~* No history of severe chronic obstructive pulmonary disease requiring 3 or more hospitalizations within the past year~* FEV_1 ≥ 1,200 cc~* No active pulmonary infection unresponsive to conventional antibiotics~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 4 weeks after study therapy~* Glucose ≤ 2 times ULN~* No more than 5% weight loss within the past 3 months~* No known allergy to murine proteins or Cremophor EL~* No neuropathy grade 2 or greater~* No other malignancy within the past 2 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other in situ cancers~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior drugs that target the epidermal growth factor receptor pathway~* No prior chimerized monoclonal antibody therapy~* No other concurrent immunotherapy~* No concurrent colony-stimulating factors (i.e., filgrastim \[G-CSF\] and sargramostim \[GM-CSF\])~  * Concurrent epoetin alfa allowed~Chemotherapy~* No prior systemic chemotherapy~* No other concurrent chemotherapy~Endocrine therapy~* No concurrent hormonal therapy except hormones for non-disease-related conditions (e.g., insulin for diabetes) or steroids for acute symptom management, adrenal failure, septic shock, or as antiemetics~Radiotherapy~* No prior thoracic or neck radiotherapy~* No concurrent intensity-modulated radiotherapy~Surgery~* Recovered from prior exploratory thoracotomy~* No prior surgical resection of the present cancer~Other~* More than 30 days since prior participation in another clinical trial~* No concurrent participation in another clinical trial~* No other concurrent anticancer therapy~* No amifostine during or for 3 months after study radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).